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Previously, we demonstrated that CD38, a transmembrane protein with ADP-ribosyl 
cyclase activity, plays a critical role in mouse social behavior by regulating the release 
of oxytocin (OXT), which is essential for mutual recognition. When CD38 was 
disrupted, social amnesia was observed in Cd38 knockout mice. The autism spectrum 
disorders (ASDs), characterized by defects in reciprocal social interaction and 
communication, occur either sporadically or in a familial pattern. However, the etiology 
of ASDs remains largely unknown. Therefore, the theoretical basis for pharmacological 
treatments has not been established. Hence, there is a rationale for investigating single 
nucleotide polymorphisms (SNPs) in the human CD38 gene in ASD subjects. We found 
several SNPs in this gene. The SNP rs3796863 (C > A) was associated with 
high-functioning autism (HFA) in American samples from the Autism Gene Resource 
Exchange. Although this finding was partially confirmed in low-functioning autism 
subjects in Israel, it has not been replicated in Japanese HFA subjects. The second SNP 
of interest, rs1800561 (4693C > T), leads to the substitution of an arginine (R) at codon 
140 by tryptophan (W; R140W) in CD38. This mutation was found in 4 probands of 
ASD and in family members of 3 pedigrees with variable levels of ASD or ASD traits. 
The plasma levels of OXT in ASD subjects with the R140W allele were lower than 
those in ASD subjects lacking this allele. The OXT levels were unchanged in healthy 
subjects with or without this mutation. One proband with the R140W allele receiving 
intranasal OXT for approximately 3 years showed improvement in areas of social 
approach, eye contact and communication behaviors, emotion, irritability, and 
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aggression. Five other ASD subjects with mental deficits received nasal OXT for 
various periods; three subjects showed improved symptoms, while 2 showed little or no 
effect. These results suggest that SNPs in CD38 may be possible risk factors for ASD 
by abrogating OXT function and that some ASD subjects can be treated with OXT in 
preliminary clinical trials. 
 





 Oxytocin (OXT) is a nonapeptide secreted into the brain from the 
oxytocinergic neurons in the paraventricular and supraoptic nuclei of the hypothalamus 
(Brownstein et al., 1980; Neuman et al., 1994 and 1996; Russell et al., 2003; Ludwig 
and Leng, 2006; Ross and Young, 2009), which is linked to complex social behaviors 
(Carter, 2003: Insel and Fernald, 2004; Donaldson and Young, 2008; Carter et al., 2009; 
Skuse and Gallagher, 2009; Ebstein et al., 2009; Insel, 2010; Higashida et al., 2007 and 
2010). In humans, intranasal administration of OXT may promote trust (Kosfeld et al., 
2005), generosity (Zak et al., 2007), gaze (Guastella et al., 2008a), mind-reading 
(Domes et al., 2007), and face recognition (Rimmele et al., 2009), as summarized in 
recent reviews (Heinrichs et al., 2009; Yamasue et al., 2009; Meyer-Lindenberg et al., 
2011; Bartz et al., 2011). However, it has recently been noted that the effects of OXT 
are context- or situation-dependent (Bartz et al., 2011). Nasal administration of OXT 
can increase social contact without severe aversive effects (Yamasue et al., 2009; 
Ebstein et al., 2009: Munesue et al., 2010; MacDonald et al., 2011). 
 In voles and rodents, OXT is closely involved in social interactions, social 
recognition, pair bonding, and maternal behavior (Carter et al., 1992; Winslow and Insel, 
2004; Insel and Fernald, 2004; Young and Wang, 2004; Young, 2007; Neumann, 2008; 
Donaldson and Young, 2008; Insel, 2010; Higashida et al., 2010). In addition, animal 
studies have shown that increased levels of OXT in the early postnatal period may 
affect behavior and last into adulthood (Young et al., 1997; Bridges, 2008; Carter et al., 
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2009). Subcutaneous administration of low doses of OXT facilitates social recognition 
(Popik, 1992). Two types of mice with OXT or OXT receptor gene knockout (Oxt−/− or 
Oxtr−/−) showed profound social amnesia (Nishimori et al., 1996; Ferguson et al., 2000; 
Takayanagi et al., 2005; Crawley et al., 2007; Macbeth et al., 2010; Sala et al., 2011), 
which was rescued by administration of OXT. These observations suggest that OXT 
plays an important role in social behavior by the stimulation of OXT receptor (OXTR) 
during brain development throughout the juvenile and adult stages (Ahern and Young, 
2009; Carter et al., 2009; Insel, 2010; Bales et al., 2011) and suggest that dysfunction of 
OXT relate with generation of autism spectrum disorders (ASDs) in which social 
recognition and reciprocal social interaction are commonly disturbed (Frith and Frith, 
2010). 
 
2. CD38 and ADP-ribosyl cyclase  
CD38 (Malavasi et al., 2008), a type II transmembrane protein (Lee, 2001; Higashida et 
al., 2007 and 2001a; Boittin et al., 2003; Guse, 2005; Ceni et al., 2006). ADP-ribosyl 
cyclase produces cyclic ADP-ribose (cADPR) from β-NAD+ (Vitamin B3; Denu, 2005), 
which is an abundant substrate in the brain. CD38 was originally examined extensively 
in the field of immunology because it controls chronic leukocyte leukemia malignancy 
and is a marker of HIV infection in blood cells (Malavasi et al., 2008). The actual 
functions of CD38 and ADP-ribosyl cyclase in the nervous system were not clear until 
our recent report, in which we demonstrated that CD38 is required for social behavior in 
ICR mice (Jin et al., 2007).  
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cADPR is a potential intracellular second messenger and a cofactor for Ca2+ 
mobilization through Ca2+-permeable channels (Ca2+-induced Ca2+ release, CICR; Lee, 
2001; Higashida et al., 2001a and b; Endo, 2009) from ryanodine-sensitive Ca2+ pools, 
resulting in increases in cytosolic free Ca2+ concentrations ([Ca2+]i). Therefore, it is 
estimated that some cellular events, such as secretion or cell migration, depend on the 
formation of cADPR and binding of cADPR to type II ryanodine receptors in various 
tissues (Guse and Lee, 2008; Shawl et al., 2009; Malvasi et al., 2008). In addition, we 
have shown that CD38 is required for social behavior by regulating OXT secretion from 
the hypothalamus and pituitary in mice by decreased formation of cADPR and resulted 
in low CICR (Jin et al., 2007; Higashida et al., 2010; Salmina et al., 2010). Consistent 
with these results, we showed that social amnesia is induced by reducing OXT secretion 
in the hypothalamus (Jin et al., 2007; Higashida et al., 2010) when ADP-ribosyl cyclase 
is reduced by CD38 gene manipulation. 
 
3. Social amnesia in Cd38 knockout mice 
 Mice lacking the Cd38 gene (Cd38-/-) are viable and fertile, grow well, and gain 
weight (Kato et al., 1999; Liu et al., 2008) from the infant stage with the dam’s milk to 
the adult stage after weaning onto solid food (Supplementary Figure S1 in Jin et al., 
2007). Similarly, Nishimori et al. (1996) reported that mice lacking Oxt (Oxt-/-) are viable 
and fertile. Although Cd38-/- mice showed no deficits in lactation/milk ejection, all Oxt-/- 
offspring die shortly after birth because of the dam’s inability to nurse. However, 
postpartum injection of OXT into Oxt-/- dams restores milk ejection and rescues the 
 7 
offspring (Nishimori et al., 1996). Similarly, Oxtr-/- mice are viable and have no obvious 
defects in fertility or reproductive behavior. In addition, Oxtr-/- dams exhibit normal 
parturition, but with defects in lactation and maternal nurturing (Takayanagi et al., 2005; 
Sala et al., 2011). These results indicate that in the OXT/CD38/OXTR signaling pathway, 
OXT and OXTR are not essential for normal parturition but are required for milk ejection, 
although CD38 is not critically involved in reproduction. 
 Cd38-/- male pups on postnatal day 7 showed significantly higher levels of 
locomotor activity during the first 3 min after separation from the dam when they were 
examined individually in the grid-crossing test in an observation chamber (Liu et al., 
2008). Both Cd38-/- and Cd38+/+ pups emitted ultrasonic vocalization (USV) upon 
isolation. The USV calls per 2-min session were less frequent in Cd38-/- pups than 
wild-type controls, with an average reduction of 38% (Liu et al., 2008; Table 1 in 
Higashida et al., 2010) although the general properties of USV were similar in both 
genotypes. Locomotor activity was examined in the interacting plate by observing 4 
pups simultaneously; Cd38-/- pups exhibited less interaction than the controls (Liu et al., 
2008), suggesting that Cd38-/- pups retain the ability to interact socially to a lesser 
extent. 
 Young adult male mice investigate intruder females (Ferguson et al., 2000). 
Cd38+/+ males that experienced repeated pairings with the same conspecifics showed a 
significant decline in the time spent investigating the female upon subsequent 
presentations of the same animal (Fig. 1). This was not due to a loss of interest but the 
retained memory of the paired female, as suggested by Ferguson et al. (2000). The adult 
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males did not need to investigate further because they recognized the paired female as 
their mate. In contrast, Cd38-/- males showed sustained high levels of investigation at 
each encounter with the same female and the same level of investigation (Jin et al., 
2007). This abnormality in social memory found in Cd38-/- mice is due to the males’ 
amnesia of conspecifics, which resembles a memory deficit observed in Oxt-/- and 
Oxtr-/- mice (Ferguson et al., 2000; Takayanagi et al., 2005; Sala et al., 2011). 
Surprisingly, abnormal investigation behavior of Cd38-/- males was rescued immediately 
by OXT (less than 20 min after subcutaneous injection) and completely normal 
behavior was observed in Cd38-/- males infected via the third ventricle with lentivirus 
harboring human CD38, and thus re-expressing human CD38 locally in the 
hypothalamic area (Jin et al., 2007).  
 Normal dams retrieved the given 5 biological pups precisely and quickly 
(average latency, 43 ± 3 s, n = 10) to the same small arena (nest) from the remote 
point in their home cages (Jin et al., 2007; Higashida et al., 2010), while Cd38-/- dams 
took a significantly longer time to begin retrieval (average latency, 76 ± 8 s; P < 
0.01, n = 18; Fig. 1) and moved around as if their interest was drawn to many things 
other than the pups (Lopatina et al., 2011). In addition, they often dropped the pups 
during retrieval as if they did not remember the way to the nest or its location, and this 
resulted in the pups becoming scattered throughout the cage. However, Cd38-/- dams fed 
the pups in their nest 30 min or more after stressful isolation. The impairment of 
retrieval reported in Oxtr-/- dams is similar to that in Cd38-/- females. These results seem 
to indicate neglect-like abnormalities in the maternal nurturing behavior of postpartum 
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Cd38-/- mice under stressful conditions, such as separation. Interestingly, this behavior 
was rescued immediately by subcutaneous injection of OXT or chronically in mice 
re-expressing human CD38 in the hypothalamic region due to a lentiviral vector (Jin et 
al., 2007) and was improved considerably with reproductive experience (Lopatina et al., 
2011).  
 
4. Low oxytocin levels in mice 
  In comparison with wild-type controls, Cd38-/- mice have reduced OXT levels 
in the plasma and cerebrospinal fluid (CSF), but elevated levels in the hypothalamus 
and pituitary tissues (Fig. 2). Interestingly, plasma vasopressin levels were almost 
equivalent in both genotypes. These observations indicated that, although OXT is 
produced and packaged into the vesicles and stored in Herring bodies in the 
hypothalamic neurons and posterior pituitary nerve endings in Cd38-/- mice, it is not 
released into the brain and bloodstream. Indeed, the plasma and CSF levels of OXT in 
Cd38-/- mice could be normalized by a single subcutaneous injection of OXT, probably 
because OXT is passed to the brain (see Supplementary Fig. S7 of Jin et al., 2007). The 
similar path of OXT from the body to the brain in humans was reported (Born, 2002; 
Meyer-Lindenberg et al., 2011). Furthermore, a genetic approach involving the infusion 
of a virus carrying the human CD38 gene into the third ventricle of knockout mice 
resulted in normalization of the plasma and CSF OXT levels, thereby normalizing 
social memory (see Fig. 2 of Jin et al., 2007). These observations indicated that the 
mechanisms underlying social behavior require CD38-dependent OXT secretion (Fig. 
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3).  
 Arginine vasopressin (AVP) release was relatively insensitive to the CD38 null 
mutation, suggesting that OXTnergic and AVPnergic neurons could be differentially 
controlled by CD38. It is not clear why CD38 mutation is insensitive to AVP neurons at 
this moment. Given the general role of cADPR in mobilizing Ca2+ from stores, other 
neurotransmitter, such as serotonin, or peptide systems could be affected. The detection 
of dopamine by microdialysis was not impaired in Cd38-/- mice (Jin et al., 2007), 




5. Contribution of TRPM2 channels to secretion in NG108-15 hybrid cells 
 We measured [Ca2+]i in neuroblastoma × glioma hybrid NG108-15 cells 
(Nirenberg et al., 1983) before and after stimulation with extracellularly applied 50 µM 
cADPR. NG108-15 cells exhibited small but significant increases in [Ca2+]i in response 
to cADPR at 35°C. The average [Ca2+]i after cADPR stimulation was 121% (n = 4; P 
< 0.01) of the pre-stimulation level (Amina et al., 2010). Surprisingly, NG108-15 cells 
showed significantly greater increases upon extracellular challenge with 50 µM cADPR 
together with heating to 40°C (Fig. 4). The average peak level was 169% (n = 5; P < 
0.01), which was significantly larger than that at 35°C (P < 0.001). These [Ca2+]i 
amplifications in response to the combination of heat and cADPR were very similar to 
those observed in HEK-239 cells expressing TRPM2 channels (Togashi et al., 2008). 
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NG108-15 hybrid cells showed TRPM2 mRNA expression as determined by RT-PCR.  
 Next, we examined cADPR-mediated changes in [Ca2+]i at 40°C in the absence 
of extracellular Ca2+. Little or no [Ca2+]i elevation was observed (103% of the 
prestimulation level; n = 4), strongly suggesting that Ca2+ influx, probably through 
non-selective cation TRPM2 channels, was triggered in response to the combination of 
cADPR and heat. The TRPM2 channel inhibitor, 2-aminoethoxydiphenyl borate 
(2-APB; Togashi et al., 2008), at a lower concentration (30 µM) inhibited Ca2+ influx 
through TRPM2 channels activated by cADPR and heat. Therefore, we postulated that 
the OT could induce [Ca2+]i elevation, elicited by cADPR in two ways (Amina et al., 
2010): (1) Ca2+ release mediated through ryanodine receptors in a PKC-dependent 
manner and (2) Ca2+ influx through TRPM2 channels, as shown schematically in Fig. 5. 
It will be of interest to examine the extent to which TRPM2 channels can contribute to 
[Ca2+]i increases in hypothalamic neurons or neurohypophyseal nerve endings, leading 
to effective OT release. 
 
6. Human CD38  
 The neurobiological basis of ASDs remains to be elucidated. Given the role of 
CD38 in social recognition in OXT release, it is possible that CD38 plays a role in the 
etiology of ASDs. Here, we discuss studies of the association between CD38and autism, 
and present several ASD cases with long-term clinical treatment with OXT. 
CD38 mRNA expression in the human brain was examined by quantitative 
RT-PCR using commercially available human brain mRNAs as templates; the highest 
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level of CD38 was found in the hypothalamus (Munesue et al., 2010), as also reported 
in mice (Jin et al., 2007). The human CD38 protein was detected in the hypothalamus of 
American and Japanese postmortem human brains using anti-human CD38 antibody. 
These results suggest that CD38 plays a similar role in both human and mouse social 
behavior (Higashida et al., 2007; Salmina et al., 2010). 
 The human gene encoding CD38 is located on human chromosome 4 at 
position p15 (Nakagawa et al., 1995; Nata et al., 1997; Malavasi et al., 2008) and 
consists of 8 exons, spanning a genomic stretch of 70.5 kb (Fig. 6). In the first set of 
cohort studies, single nucleotide polymorphisms (SNPs) and mutation screening in 8 
exons and their flanking introns were performed in 29 unrelated ASD subjects fulfilling 
the Diagnostic and Statistical Manual for Mental Disorders, Fourth edition (DSM-IV) 
and CASK criteria for ASD and in 201 non-clinical control subjects in the Kanazawa 
area, Japan. We detected 12 SNPs that have already been reported, along with 5 novel 
SNPs and mutations with or without amino acid alterations only in ASD subjects and/or 
control subjects. 
 
7. Intronic rs3796863 SNP of human CD38 
 The rs379863 (C > A) SNP of CD38 in intron 7 showed a significant 
association with 147 American patients with high-functioning autism (HFA) (P < 
0.005), but not in 182 Japanese HFA patients (P = 0.23) (Munesue et al., 20010), 
which is ethnically specific. The reason why this association was found in only 
American, but not Japanese, HFA patients is not clear. This is one of few common 
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variants that may contribute to the genetic susceptibility to HFA (Nakamura et al., 2008; 
Wermter et al., 2010). Based on our results of SNP and haplotype transmission 
disequilibrium test analyses, the C allele of rs3796863 in CD38 may be considered a 
protective allele (Fig. 6) and the A allele may be a risk allele in American HFA cases 
(Fig. 4 in Munesue et al., 2010). These results were partially reproduction by Lerer et al. 
in 170 Israeli ASD patients (2010). They showed that rs3796863 has a significant 
association with low-functioning autism, but not necessarily with HFA. 
 This variant is common with an allele frequency of about 0.3. Very recently, 
common variants on chromosome 5p14.1, together with 6 meaningful variants between 
neural cadherin 10 and 9, have been reported to be associated with ASD (Wang et al., 
2009). As rs3796863 is an intronic SNP, the functional importance of this SNP 
remained to be examined. Lerer et al. (2010) suggested that this allele may contribute to 
the decreased expression of CD38 in ASD subjects based on analysis of immortalized 
lymphoid cells from ASD subjects and their non-idiopathic parents. In addition, they 
suggested that retinoids may be have therapeutic potential to increase CD38 expression 
in ASD subjects, as shown in Fig. 7 (Riebold et al., 2011; Ebstein, 2011). Very recently 
it was reported that CD38 is closely related to disfunction of OXT secretion in ASD 
patients (Kiss et al., 2011). Therefore, it is possible that CD38 regulates OXT release in 
the brains of normal and ASD subjects (Munesue et al., 2010).  
 
8. Exonic rs1800161 SNP of human CD38 
 Among the SNPs in exons shown in Fig. 6, we focused on the C4693T 
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mutation in exon 3 (rs1800561) that leads to an arginine (R)-to-tryptophan (W) 
substitution at amino acid 140 (R140W). Interestingly, R140 is located in the flexible 
loop (amino acid residues 137 – 141) at the midpoint of the N- and C-terminal 
domains between 2 helical domains (αa4 and αa5), and is the pivot of the hinge region 
connecting two regions of the L-shaped molecule (Munesue et al., 2010). Therefore, the 
R140W mutation causes significant modifications and damage to the predicted protein 
structure in comparison with the human wild-type (R140R) CD38 (see Fig. 7 of 
Munesue et al., 2010). It has been reported that the mutant R140W-CD38 showed 
one-third of the ADP-ribosyl cyclase activity of R140R CD38 when expressed in CHO 
cells (Yagui et al., 1998). Shown as the in vivo effect, social amnesia was not rescued 
by the local expression of human R140W-CD38 by lentivirus infection in the 
hypothalamus of Cd38 knockout mice (Fig. 2 of Jin et al., 2007).  
 Heterozygosity for 140R/W (C4693T) was found in 3 male subjects (2 autistic 
and 1 Asperger) among 29 ASD subjects examined (23 males and 6 females; mean age, 
22.8 ± 7.6 years; allele frequency, 0.052). Two females and 1 male among 315 
healthy unscreened controls were positive for the heterozygous mutation, representing 
an allele frequency of 0.0048 (Munesue et al., 2010). This frequency was 10.8-fold 
lower than that in the ASD patient group from the same residential area (P < 0.029). 
 This SNP is relatively frequent in the Asian population (see Munesue et al., 
2010), but was very infrequent in 551 white (non-Hispanic and non-Latino) subjects in 
Autism Genetic Resource Exchange (AGRE) samples, although recently we found one 
heterozygous ASD patient with this SNP. These results suggest that the mutation is 
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carried mostly by the general Asian population. 
Next, we examined whether the R140W allele co-segregated with ASD and 
ASD-related traits in 3 proband families in the above group. Twenty-five members of 
the 3 kindred families were available for detailed clinical and genetic analyses. The 
4693 C-to-T SNP was found in all proband fathers of the 3 families and in the brothers 
belonging to 2 families. The mutation is apparently an autosomal dominant trait. We 
identified 18 carriers in 29 family members who agreed to be tested. In all cases, the 
mutation was heterozygous (allele frequency = 0.32). The mutant allele was indeed 
transcribed in the subjects tested (Munesue et al., 2010; Higashida et al., 2010).  
 The probands’ younger (Fig. 8C) and older (Fig. 8D) brothers showed clinical 
features consistent with ASD. Two fathers in their 50s and another father in his 70s 
were diagnosed with ASD traits. Most other adults over 50 years of age in these 
pedigrees had not been clinically diagnosed with ASD or other psychiatric diseases and 
adapted well to acquire daily living skills. Two female cousins with the R140W allele 
did not show ASD traits. These data suggest that this R140W allele is necessary but not 
sufficient for ASD. 
 Furthermore, we evaluated these subjects using the Japanese version of the 
Autism Spectrum Quotient behavioral test (AQ; Munesue et al., 2008), in which older 
subjects self-reported behaviors in their 20s. AQ scores in 2 young male carriers in the 
families fulfilled the criteria (cut-off point of 28) for ASD, indicating that such carriers 
will manifest ASD. These clinical and self-describing evaluations suggest that this 
mutation is important in determining ASD or phenotypes of ASD-related traits. 
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9. Oxytocin and vasopressin levels in control and ASD subjects 
Given these results, we obtained serum samples from the kindred to further 
study the connection between the human CD38 mutation and plasma OXT or arginine 
vasopressin (AVP) levels, as slow levels of OXT have been reported in autistic children 
(Modahl et al., 1998). Plasma OXT levels in the R140W carriers (161.3 ± 26.5 pg/ml; 
n = 12) were lower than those in the kindred non-carriers (345.8 ± 61.3 pg/ml; n 
= 10; P < 0.01) (Fig. 8). The OXT levels of 3 probands and 2 young carriers were 
compared with those of ASD subjects lacking the W140 mutation: the levels of five 
W140 carriers (79.2 ± 16.6 pg/ml; n = 5; Munesue et al., 2010) were lower than 
those of ASD subjects lacking the mutation (147.7 ± 15.0 pg/ml; P < 0.01; n = 
26). Furthermore, the OXT levels of ASD probands with the W140 allele were 
significantly lower than those in 101 control adults (198.2 ± 24.7 pg/ml; P < 0.01). 
The OXT levels were not lower in control subjects with than in those without the W140 
allele (Fig. 8E).  
Furthermore, there were no differences in AVP levels of the CD38 SNP 
carriers and non-carriers in the pedigrees (data not shown). These observations were 
consistent with the working hypothesis that CD38 is related only to OXT release but not 
to AVP release. 
 
10. Progression and regression by nasal oxytocin administration 
 In June 2008, we were informed by the mother of one (Fig. 8D) of three 
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probands, a 23-year-old man with autism, that she had begun giving her son OXT (one 
puff per nostril every morning and evening; 16 IU/day, 40 IU/ml Syntocinon spray; 
Novartis). As this patient had the C4693T (rs1800561) polymorphism and plasma OXT 
levels were lower than control adult males (Fig. 8A and B), his parents decided to 
personally provide OXT. His behavioral symptoms showed considerable progress with 
the regular use of OXT for 36 months (Table 1). At the periodic clinical checkup, he 
made good eye contact with the one of authors and even had a friendly appearance with 
a smile and improved gaze. He could answer yes/no questions (i.e., “Did you sleep well 
last night?”) and even some alternative questions such as “Is it fair or cloudy today?” 
with enhanced communication. His intelligence quotient (IQ) was measured 
successfully in January 2009 (IQ = 21) using the Japanese version of the 
Stanford–Binet Intelligence Scale, although IQ could not be measure before OXT 
treatment. When he stopped taking OXT for three months, his behavior dropped to the 
original low level and again his IQ could not be measured. However, renewing the OXT 
intake of two puffs every morning was accompanied by recovery. 
   
11. Personal and relatively long-term use of oxytocin in ASD subjects 
As we experienced some effectiveness of OXT in the above patient with the 
R140W SNP, we reconsidered the use of OXT as a possible treatment for ASD. 
Psychopharmacological interventions have been conducted in the treatment of ASD 
subjects. However, all agents examined to date showed either limited or no 
effectiveness in ameliorating ASD symptoms. For example, risperidone, a 
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second-generation antipsychotic, was suggested to be effective in managing irritability 
such as tantrums, aggression, and self-injurious behavior in ASD subjects, but not social 
withdrawal and inappropriate speech (McCracken et al., 2002). Although selective 
serotonin reuptake inhibitors (SSRI) are the most frequently used medications for ASD 
subjects (Esbensen et al., 2009), citalopram, an SSRI, showed little or no efficacy in 
treating social withdrawal, inappropriate speech, and repetitive behavior in a 
well-designed controlled study (King et al., 2009). Notably, conventional medications 
showed no beneficial effects on impairment of social interaction such as reciprocal 
communication, which are core symptoms in ASD subjects. Although OXT is only 
approved for induction of labor by intravenous injection in most countries, it is freely 
available as a nasal spray. Thus, ASD individuals may use the OXT nasal spray to 
reduce the various constraints in their daily life (MacDonald and Macdonald, 2010; 
Kuehn, 2011). To date, no randomized controlled trials of OXT have been published 
regarding its use in the treatment of ASD subjects. 
    Intellectual levels of ASD range from profound disability to excellent. ASD 
subjects with severe or profound mental deficiency are heavy burdens on their 
caregivers from infancy to adulthood because of their troublesome behaviors, such as 
lack of communication and effective contact, hyperkinesis, temper tantrums, self-injury, 
screaming, incomprehension of social common sense, and aggression (Lecavalier et al., 
2006). As we have already noted that ASD subjects receive some benefits from the 
personal use of the OXT nasal spray (Munesue et al., 2010), we have received many 
inquiries by caregivers of ASD individuals regarding OXT use, most of whom suffered 
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from severe and profound mental deficiencies. 
Twenty-seven ASD individuals participated in our ASD genetic study, which 
was approved by Kanazawa University Medical Committee of Ethics. Written informed 
consent was obtained from the parents of all subjects prior to enrollment in the study. 
Three subjects who later began to personally take OXT through intranasal 
administration (Table 1) were diagnosed as having an autistic disorder based on 
DSM-IV (American Psychiatric Association) and using the Diagnostic Interview for 
Social and Communication Disorders (Wing et al., 2002). Their intelligence levels 
could not be measured because of lack of cooperation, and they were estimated to have 
severe or profound mental disabilities. One patient (case 2 in Table 1), who had been 
treated by one of the authors for epilepsy, personally used the OXT nasal spray for 1 
year. Although he did not participate in our genetic study, he was diagnosed with autism 
and severe mental retardation in infancy by a psychiatrist.  
    In summary, 6 male adolescents and adults with ASD were nasally administered 
OXT for periods between 4 months and 2 years based on their caregiver’s personal 
decision (Table 1). All of them suffered from an estimated severe or profound 
impairment of intelligence. Previously prescribed medications appeared ineffective 
according to their caregivers, except for antiepileptic medications, which were helpful 
in treating the epilepsy in case 6. The caregiver’s global impressions of the 
effectiveness of OXT were “much improved” in 3 subjects, “minimally improved” in 1 
subjects, and “no change” in 2 subjects. Appreciable adverse effects have not been 
reported by their caregivers. These findings were in accordance with those reported by 
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MacDonald et al. (2011). These observations from personal use of OXT are discussed 
below. 
    First, eye-to-eye gaze improved in 3 subjects, and the ability to converse developed 
in another 3 subjects, as expected from the results in healthy subjects (Guastella et al., 
2008a and b; Ditzen et al., 2009) and autistic patients (Hollander et al., 2007). Despite 
the impairment of intelligence, 4 of 6 subjects appeared to be able to considerably 
establish reciprocal social interactions. Although observer bias and inherent 
development should be taken into consideration as causes of improvements, caregivers 
were more comfortable with ASD subjects after they began taking OXT. However, 3 
subjects were in late adolescence; thus, these improvements could be regarded as due to 
inherent development. However, as one subject was near middle age, his improvement 
was unlikely to have been due to such inherent development. 
    Second, according to their caregivers, irritability or aggression decreased or even 
disappeared in 3 subjects after commencement of OXT treatment. One patient, who had 
strongly persisted in buying particular goods at a supermarket whenever he went with 
his family has now complied with his caregiver’s instructions to not adhere to such 
restricted patterns of activities after taking OXT. These explicit changes are not 
interpreted as indicative of observation bias. Third, it remains unclear why 2 subjects 
did not show behavioral improvements with OXT administration. Finally, the results of 
this case series indicated that OXT may be an effective treatment for ASD subjects, and 




Recent genetic and biological studies indicated that defects in OXT signaling 
confer vulnerability to ASD. CD38 SNPs appear to provide a genetic basis for cases of 
ASD that arise from the disruption of OXT signaling. Furthermore, although the 
R140W mutation was found in 1 of 445 American AGRE samples, the association study 
with Tag SNPs showed 1 SNP (rs3796863) in CD38 that was positively correlated with 
American HFA or Israeli ASD patients. Therefore, it is possible that CD38 mutations 
may provide a genetic basis for such cases of ASD, and this was replicated recently in 
two studies (Kiss et al., 2011; Feldman et al., 2011). CD38 SNPs may cause lower OXT 
levels in ASD subjects. However, we do not know whether clinically unaffected carriers 
with this mutant allele in families and general populations may be influenced by 
compensatory factors for ASD (Fig. 9). To our knowledge, this is the first report to 
show the therapeutic effects of OXT on the social deficits in a limited number of ASD 
patients in terms of long-term benefits and real-life situations. However, its efficacy was 
based on self-judgment, including parental reports and doctor’s judgment determined 
from clinical interviews. Thus, the effects of OXT should be tested by clear objective 
scales in future studies. Despite the limitation of the absence of control trials, 
observations of subjects in our clinical office and in their homes by their parents, as 
noted in the reports, are potentially clinically relevant in evaluating the contribution of 
OXT to the core behavioral domains (social and communication behaviors) of ASD 
subjects. In addition, aggression and irritability due probably to anxiety frequently 
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Table 1. Personal use of oxytocin for over 3 months by male ASD patients with severe mental deficit 
with (case 1) or without (others) the R104W SNP 
 
 
Case   Medications*  Age  Duration**  Behavior      Judgment 
      Rate of improvement  
 
1 Risperidone  21  36    minimal  Eye-to-eye gaze      
          Conversation   
            
2  Not used    19   4  much Eye-to-eye gaze   
       Aggression   
      Irritability    
       Sensory hypersensitivity  
            
3 Aripiprazole   17  12     much Conversation   
      Aggression   
       Irritability    
      Self-injury   
 
4 Not used    15   3     no change 
 
5 Valproate   13   5  no change 
 
6 Valproate   38  12 much Eye-to-eye gaze   
 Phenytoin     Conversation   
 Carbamazepine          Irritability    
      Repetitive behavior   
            
*Medication indicates simultaneous treatment with drugs during intranasal OXT administration. 





Fig, 1 Social behavior of CD38 knockout mice and effects of oxytocin injection or 
lentiviral infection. Double staining for oxytocin (OXT, green) and CD38 (red) in the 
hypothalamus of male wild-type (A) or Cd38-/- (B) mice. (C). Investigation behavior of 
a male to the anogenital region of an intruder female. (D). Decrease of investigation 
time in WT (+/+) or no decrease in Cd38-/- (-/-) males. (E). Behavioral recovery in 
males subcutaneously injected with OXT (+OXT) and no recovery in control mice 
injected with saline (+NaCl) or arginine vasopressin (+AVP). (F). Average investigation 
time of two genotypes with or without local re-expression of intact human CD38 or 
mutant CD38 (R140W) in the hypothalamic regions. Retrieval behavior of wild-type 
(G) or Cd38-/- (H) dams. (I). Average time required to retrieve 5 pups by dams of two 
genotypes.  
  
Fig. 2. Oxytocin or vasopressin levels in the plasma and CSF of male mice of two 
genotypes. 
 
Fig. 3 Regulatory mechanisms affecting oxytocin activity in the context of social 
behavior. Regulation at the level of central OXT secretion is due to calcium 
amplification (CICR) by CD38 and cADPR, which seems to be critical for social 
recognition and behavior. 
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Fig. 4. Changes in [Ca2+]i induced by extracellular application of cADPR were 
coactivated by heat in NG 108-15 cells. (A and B). Representative images of 
fluorescence changes in NG108-15 cells. cADPR (50 µM) was applied extracellularly at 
the arrow. [Ca2+]i was measured at 35°C (A) or 40°C (B). Bar, 10 µm. White arrows 
and arrowheads show Oregon Green staining with a large change after stimulation. Inset, 
a larger montage of cells indicated by the arrows. (C) Time courses of changes in 
[Ca2+]i drawn from fluorescence imaging comparing stimulation at 35°C and 40°C in 
the presence of extracellular cADPR. Data are shown as changes in fluorescence 
intensity divided by the resting state, i.e., ΔF0/F1, as means ± SEM (n =  4-6). (D) 
[Ca2+]i changes obtained in NG108-15 cells challenged by heat (from 35°C to 40°C) 
and extracellular cADPR (50 µM) in the presence (◊) or absence (∆) of extracellular 
Ca2+. The effects of 2-APB on [Ca2+]i change with heat and cADPR are indicated by 
open circles (O). Values are means ± SEM of 3 – 5 cells. 
 
Fig. 5 Schematic representation of how oxytocin (OXT) is released after oxytocin 
receptor (OXTR) stimulation without depolarization via the calcium (black dots) 
amplification signal of Ca2+-induced Ca2+ release (CICR) essentially regulated by 
cyclic ADP-ribose (cADPR). CD38 with ADP-ribosyl cyclase activity in 
OXT-producing neurons in the hypothalamus, regulated by protein kinase C (PKC), can 
catalyze cADPR from β-NAD+ on either the intracellular or extracellular side. cADPR 
together with heat activate TRPM2 cation channels and facilitate Ca2+ influx and Ca2+ 
release from ryanodine receptors (RyR) on intracellular Ca2+ pools. OXT is released by 
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increased intracellular Ca2+ concentrations, which is necessary to behave well in social 
interactions. 
 
Fig. 6. Genome structure and single nucleotide polymorphisms of human CD38. 
CD38 and CD157, a gene duplication product and family gene, are located on the 
chromosome 4p15 region with the same structure (8 exons). Locations of SNPs in 
intronic SNP (SNP06), rs3796863, and exonic SNP (R140W SNP), rs1800561, are 
shown. SNPs of major allele and minor allele are shown in red with average penetration 
ratios in US and Japan, respectively.  
 
Fig. 7. Plasma oxytocin (OXT) and arginine-vasopressin (AVP) levels and two 
pedigrees of ASD probands with the R140W allele. (A) A plot of plasma OXT levels 
of 29 ASD individuals without (open circles) or with the R140W allele (pink). (B). A 
scatter plot of OXT and AVP levels ASD individuals without (closed circles) or with 
the R140W allele (pink). (C and D) Pedigrees of 2 ASD probands. Subjects represent 
carriers of the R140W allele (filled symbols) or those without (open). Green symbols 
indicate no analysis. Arrows, proband, Asp, Asperger’s disorder. (E). Plasma oxytocin 
and vasopressin levels in control subjects with or without (R140; n = 10, green or 
blue bars) heterozygous R140W allele. Circles denote females and diamonds or squares 
indicate males. Note that the plasma OXT level in W140 carriers in non-idiopathic 
controls was not low. 
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Fig. 8 Potential usage of retinoids (vitamin A analogs) or nasal oxytocin for ASD 
subjects. Expected malfunction caused by CD38 NPs. All-trans retinoic acid can 
induce CD38 transcription and results in higher CD38 expression. To rescue lower 
plasma or brain OXT levels in ASD patients, OXT may be applied by the nasal OXT 
spray method. 
 
Fig. 9. Hypothesis of how single nucleotide polymorphisms (SNPs) lead to autism 
spectrum disorder (ASD) or not (non-ASD). rs3796863 and rs1800561 SNPs of 
human CD38 may cause lower levels of oxytocin (OXT) in the brain or plasma, which 
could be used as biomarkers, through lowering the expression or enzymatic activity as 
the CD38 endophenotype. The low plasma OXT level is also produced by other 
unknown factors than CD38 SNPs (other causes). ASD may be triggered by other 
strong risk factors and/or other weaker protective factors), while ASD may not be 
induced by other weaker risk factors and/or other strong protective factors, including 
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•  SNP06 (rs3796863) 
GGGAGGGGAGCTATCCATGCCACCTGCTGGTCA  72% ? 
GGGAGGGGAGCTATCCATGCCACCTGATGGTCA  28%? 
•  SNP13 R140W (rs1800561) 
TGGCCCATCAGTTCACACAGGTCCAGCGGGACA   95-99% 
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